Actively Recruiting
Transbronchial vs Transthoracic Ablation for Early-stage Peripheral Lung Cancer
Led by Hangzhou Broncus Medical Co., Ltd. · Updated on 2023-12-06
110
Participants Needed
1
Research Sites
207 weeks
Total Duration
On this page
Sponsors
H
Hangzhou Broncus Medical Co., Ltd.
Lead Sponsor
S
Shanghai Chest Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to investigate the efficacy and safety of RFA through a transthoracic or transbronchial approach in the treatment of early-stage peripheral lung cancer.
CONDITIONS
Official Title
Transbronchial vs Transthoracic Ablation for Early-stage Peripheral Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age greater than 18 years.
- Diagnosed primary peripheral lung cancer at clinical stage T1N0M0, stage IA.
- Planned ablation lesions suitable for CT-guided and bronchoscopy-guided ablation.
- Assessed as inoperable or refused surgery, agree to initial ablation therapy, and signed informed consent.
You will not qualify if you...
- Platelet count below 50 × 10 9/L, severe bleeding risk, or coagulation problems not quickly correctable.
- Severe pulmonary fibrosis or pulmonary hypertension.
- Active infection near lesion or puncture site, uncontrolled skin infection, systemic infection, or high fever over 38.5°C.
- Severe dysfunction of liver, kidney, heart, lung, brain; severe anemia, dehydration, or severe nutritional metabolism disorders not quickly correctable.
- Poorly controlled malignant pleural effusion.
- Anticoagulation or antiplatelet therapy (except certain new oral anticoagulants) stopped less than 5-7 days before ablation.
- Eastern Cooperative Oncology Group (ECOG) score greater than 2.
- Other tumors with extensive metastasis and expected survival under 6 months.
- Episodic psychosis.
- Implantable electronic devices like pacemakers or defibrillators.
- Pregnancy or plans to become pregnant during the study.
- Participation in another clinical study within the past 30 days.
- Other conditions deemed unsuitable for participation by the investigator.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China, 200030
Actively Recruiting
Research Team
J
Jiayuan Sun, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here